[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 2001

Treatment of Refractory, Atypical Lower Extremity Ulcers With Tissue-Engineered Skin (Apligraf)

Arch Dermatol. 2001;137(12):1660-1661. doi:

The development of tissue-engineered skin (Apligraf; Organogenesis Inc, Canton, Mass), which has been approved for venous leg ulcers and diabetic neuropathic foot ulcers, has offered a new option for patients with chronic wounds.1 How tissue-engineered skin heals chronic wounds is under investigation, but it appears to work primarily as a stimulus to healing, likely through the production of various cytokines.

First Page Preview View Large
First page PDF preview
First page PDF preview